INTRODUCTION

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, accounting for more than 80% of dementia cases among the elderly around the world. By 2050, one new case of AD is expected to develop every 33 seconds, or nearly a million new cases per year [1]. Pathogenesis of AD begins with the accumulation of insoluble Amyloid β (Aβ) oligomers because of altered cleavage of Amyloid precursor protein (APP). These aggregated plaques and tangles promote the activation of microglia and astrocytes, increase mitochondrial oxidative stress, decrease energy metabolism, and cause degeneration of hippocampal pyramidal neurons [2]. Diabetes and Hyperinsulinemia occur as a result of higher body mass index (BMI) by increasing insulin resistance. Thus, it would be expected that a higher BMI would be associated with a higher risk of AD through diabetes and hyperinsulinemia-related mechanisms; some studies have suggested an association between hyperlipidemia, or high cholesterol and a higher risk of AD, particularly in middle age [3]. Brain cholesterol is a primary component of the brain membrane, and it plays a role in maintaining the plasticity of neurons. The presence of the ε4 allele of ApoE, a cholesterol carrier, represents the major genetic risk factor for the late-onset form of the disease. Another potential mechanism is cerebrovascular disease, although hypertension is a much more important risk factor for AD. The use of lipid-lowering medications could also reduce the risk of AD with widely available medication. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase) that represent the rate-limiting enzyme in cholesterol biosynthesis. These drugs are used among elderly patients to treat vascular death, stroke, and myocardial infarction.

Cholesterol levels in the brain are increased during AD condition. These regions are known as lipid rafts, and they contain β and γ secretases. These secretases are capable of
cleaving APP into sAPPβ and a membrane-bound APP-CTF (C99). The γ-secretase later cleaves the C99 into Aβ and the APP intracellular domain, which eventually results in the worsening of AD. Hence, Simvastatin, a cholesterol synthesis inhibitor, was evaluated in this study.

Acetyl-CoA is the precursor for the synthesis of cholesterol. HMG CoA reductase is inhibited by statins, which is the rate-limiting step for cholesterol synthesis. Inhibits isoprenylation, which is required for the processing of APP and inflammation [4,5]. Doxycycline is endowed with anti-amyloidogenic properties and better crosses the blood-brain barrier. AD progression is mainly due to the accumulation of Aβ, and Doxycycline inhibits the aggregation of Aβ42 Amyloid fibrils and disassembles mature Amyloid fibrils. A hopeful repositioned drug is counteracting crucial neuropathological AD targets. The present study aims to evaluate the effect of a combination of Simvastatin and Doxycycline on Aβ clearance in an Amyloid beta-induced AD mice model.

MATERIALS AND METHODS

Animals

C57BL/6 female mice of body weight 25–30 g were acquired with an IAEC approval No: JSSAHER/CPT/IAEC/081/2021. Animals were divided into groups and held in polypropylene cages in an aerated environment, retaining temperature at 23°C ± 3°C and humidity levels at 40%–70%. The rooms followed the 12 hours L and 12 hours D cycle and minimal sound (<80 decibels). Animals were fed with quality rodent feed and pure water. Animals were allowed to familiarize themselves with the new environment for 7 days before starting the experimental work. All the animal investigational procedures were approved and supervised by IAEC- JSSCPM. The female mice were used as Alzheimer’s proteins rise sharply in response to stress in female mice.[6]

Treatment drugs

The treatment drugs Simvastatin and Doxycycline and the standard drug Donepezil are procured from JSS Hospital in Mysuru, Karnataka, India.

Grouping of animals for induction of AD by mouse model

The animals were divided into groups, with 56 animals equally divided into groups (n = 7). The dose given to animals and the treatment period were mentioned in Table 1.

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. of animals</th>
<th>Treatment, dose, duration, and route</th>
<th>Evaluation parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>7</td>
<td>Normal</td>
<td>Behavioural parameters</td>
</tr>
<tr>
<td>Sham</td>
<td>7</td>
<td>5 µl of PBS i.c.v</td>
<td>Buried pellet test</td>
</tr>
<tr>
<td>Disease</td>
<td>7</td>
<td>5 µl of Aβ1-42 i.c.v (7 days induction period) + vehicle</td>
<td>MWM</td>
</tr>
<tr>
<td>Standard</td>
<td>7</td>
<td>5 µl of Aβ1-42 i.c.v + Donepezil (3.5 mg/kg i.p) 28 days</td>
<td>Biochemical parameters</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>7</td>
<td>Aβ + Simvastatin(20 mg/kg) p.o 28 days</td>
<td>Total cholesterol</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>7</td>
<td>Aβ + Doxycycline (10 mg/kg) i.p 28 days</td>
<td>High density lipoprotein (HDL)</td>
</tr>
<tr>
<td>Low dose (Simva and doxy)</td>
<td>7</td>
<td>Aβ + simvastatin(20 mg/kg) p.o + Doxycycline(10 mg/kg) i.p28 days</td>
<td>Triglycerides</td>
</tr>
<tr>
<td>High dose (Simva and doxy)</td>
<td>7</td>
<td>Aβ +simvastatin(10 mg/kg) p.o+ Doxycycline(5 mg/kg) i.p 28 days</td>
<td>Histopathology</td>
</tr>
</tbody>
</table>

Induction of Alzheimer’s by Aβ

Aβ monomer solution (1 µM) was prepared using dimethylsulphoxide and diluting it 10 times with phosphate buffer saline (PBS). Incubation of monomer solution at 37°C for 5 days under humid conditions results in oligomer formation [7]. Next, Aβ1-42 was injected by i.c.v with the help of a stereotaxic apparatus (Stoeling, USA) consisting of a 28-gauge stainless-steel needle of 3.0 mm length (Hamilton). An intraperitoneal (i.p) injection of xylazine (20 mg/kg) and Ketamine (80 mg/kg) cocktail was used for inducing anesthesia in mice, after which they were placed on a stereotaxic frame. 5 µl of Aβ1-42 was injected slowly into the right lateral ventricle using the following coordinates from bregma: anteroposterior = −0.9 mm, mediolateral = 1.3 mm, and dorsoventral = −2.0 mm. Sham-treated mice received PBS (5 µl) in the same coordinates. Special care was taken to prevent temperature falls in the mice. The rapid dispersion of the peptide throughout the brain is a real advantage of this i.c.v. mode of administration [8].

Behavioral parameters

Buried pellet

We used a buried pellet test to examine the mice’s odor detection, as previously described. Individually housed mice were fed a meal containing 90% of their body weight for two days previous to the test and for the duration of the experiment. 1–2 pieces of pellets were given to each mouse to get adjusted with the pellet throughout the test and during food restriction. This phase is crucial because the mice must become used to the pellet odor. In the test cage, a portion of the pellet was buried 0.5 cm below the bedding. The mouse was placed in the center of the cage at the start of each trial. The time required to discover the pellet was noted [9].

Morris water maze (MWM)

MWM is used to measure spatial learning and memory performance. This metallic pool was filled with water, and the temperature was maintained stable at 23°C. The light intensity, external cue, and opacity of water (with black food coloring) were made reproducible. The entire pool was segmented into four quadrants with an escape platform (diameter: 4.5 cm) kept at the southwest quadrant. 5 days of acquisition were performed, with 2 trials being performed daily for 2 days and 1 trial per day for the rest 3 days. The final 6th day was the test day. The mice were kept at random in the water, in the opposite
compared to the standard group (16.71 ± 1.16 in the time taken to unbury the buried pellet on day 35 when compared to the standard group (18.28 ± 0.99 to unbury the buried pellet on day 35 when compared to the standard group (14.66 ± 0.73 vs. 13.77 ± 0.9 and 13.61 ± 0.92 vs. 13.77 ± 0.97). A low-dose combination of (Simvastatin and Doxycycline) has shown a slight difference in a variation on day 35 when compared to the standard group (16.71 ± 1.16 vs. 16.42 ± 1.19). The effect of Simvastatin and Doxycycline on memory enhancement is reported in Figure 2 and Table 3.

Biochemical parameters

**Estimation of total cholesterol, triglycerides, and HDL**

Total cholesterol [10,11,12], triglycerides [13,14], and HDL [15,16] were estimated using kit method.

**Histopathology**

The brains were removed from the animals, and the tissues were stored in 10% formalin. The brains were removed and postfixed in the same fixative overnight at 48°C. The brains were embedded in paraffin and stained with Hematoxylin-Eosin. The hippocampus lesions were assessed microscopically at 400× magnifications.

**Statistical analysis**

For in vivo, the values are expressed as mean ± SEM of samples. All data were analyzed by one-way ANOVA followed by Tukey’s post-hoc test using Graph pad Prism version 5.0 software. The difference between the control and treated groups was expressed using a p-value, and considered significant if p < 0.05.

**RESULTS**

**Behavioral parameters**

**Effect of Simvastatin and Doxycycline on olfactory function after Aβ induction in mice**

Sham control did not show any significant changes in the time spent in the target quadrant from day 0 to 28 (15.21 ± 2.05 vs. 15.65 ± 1.00). The disease group showed a decrease in the time spent in the target quadrant from day 0 to 28 (17.32 ± 0.51 vs. 10.61 ± 1.62) when compared to normal. Simvastatin- and Doxycycline-treated groups have not shown any significant difference in time spent in the target quadrant on day 28 when compared to the standard group (14.66 ± 0.73 vs. 13.77 ± 0.9 and 13.61 ± 0.92 vs. 13.77 ± 0.97). A low-dose combination of (Simvastatin and Doxycycline) has shown a significant difference in time spent in the target quadrant on day 28 when compared to the standard group (15.24 ± 0.80 vs. 13.77 ± 0.9 and 13.61 ± 0.92 vs. 13.77 ± 0.97). A high-dose combination of Simvastatin and Doxycycline has a slight difference in a variation on day 35 when compared to the standard group (16.71 ± 1.16 vs. 16.42 ± 1.19). The effect of Simvastatin and Doxycycline on memory enhancement is reported in Figure 2 and Table 3.

**Biochemical parameters**

**Effect of Simvastatin and Doxycycline on total cholesterol after Aβ induction in mice**

The sham group did not show any significant increase in total cholesterol when compared to normal (38.92 ± 2.37 vs. 40.31 ± 2.73). The disease group has shown an increase in the amount of total cholesterol when compared to normal (59.89 ± 0.95 vs. 40.31 ± 2.73). Simvastatin-treated group has shown a decrease in the amount of total cholesterol when compared to the disease group (37.68 ± 2.48 vs. 59.89 ± 0.95). Doxycycline-treated group has shown a less significant decrease in the amount of total cholesterol when compared to the disease group (52.39 ± 0.85 vs. 59.89 ± 0.95). In a low-dose combination of Simvastatin and Doxycycline and a high-dose combination of Simvastatin and Doxycycline, a treated group has shown a

![Figure 1. Effect of Simvastatin and Doxycycline on buried pellet test after Aβ induction in mice. All values are expressed in the form of Mean ± SEM, n = 7; data were analyzed by employing two-way ANOVA and “a” represents p-value <0.05 when compared to normal versus disease, and “b” represents p-value <0.05 when compared to disease versus treatment groups.](image-url)
Table 2. Effect of Simvastatin and Doxycycline on buried pellet test after Aβ induction in mice.

<table>
<thead>
<tr>
<th>Days</th>
<th>Normal</th>
<th>Sham</th>
<th>Disease</th>
<th>Standard</th>
<th>Simvastatin</th>
<th>Doxycycline</th>
<th>Low dose (Simva and Doxy)</th>
<th>High dose (Simva and Doxy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>9.14 ± 0.70</td>
<td>8 ± 1.04</td>
<td>8.42 ± 0.94*</td>
<td>8.14 ± 0.50</td>
<td>7.28 ± 0.68</td>
<td>9 ± 0.69</td>
<td>7.85 ± 0.73</td>
<td>7.85 ± 0.70</td>
</tr>
<tr>
<td>7</td>
<td>9 ± 0.89</td>
<td>11.8 ± 0.96</td>
<td>23.42 ± 2.85</td>
<td>25.42 ± 1.92</td>
<td>23.85 ± 2.98</td>
<td>27 ± 2.26</td>
<td>26.57 ± 1.36</td>
<td>26.42 ± 1.78</td>
</tr>
<tr>
<td>14</td>
<td>8.57 ± 0.75</td>
<td>9.42 ± 0.68</td>
<td>26.14 ± 1.42*</td>
<td>21.14 ± 0.94</td>
<td>22.85 ± 2.14*</td>
<td>23.71 ± 2.21*</td>
<td>23.57 ± 0.92*</td>
<td>23.14 ± 1.18*</td>
</tr>
<tr>
<td>28</td>
<td>7 ± 0.65</td>
<td>7.57 ± 0.81</td>
<td>28.42 ± 1.74</td>
<td>18.14 ± 0.67</td>
<td>19.71 ± 0.91</td>
<td>21.28 ± 1.37</td>
<td>21 ± 0.69</td>
<td>19.28 ± 0.77</td>
</tr>
<tr>
<td>35</td>
<td>7.42 ± 0.36</td>
<td>8.57 ± 0.57</td>
<td>28.28 ± 1.26*</td>
<td>16.42 ± 1.19</td>
<td>18.28 ± 0.99*</td>
<td>18.85 ± 1.28*</td>
<td>17.42 ± 0.84*</td>
<td>16.71 ± 1.16*</td>
</tr>
</tbody>
</table>

All values are expressed in the form of Mean ± SEM, n = 7; data were analyzed by employing Two-way ANOVA, and “a” represents p-value < 0.05 when compared to normal versus disease, and “b” represents p-value < 0.05 when compared to disease versus treatment groups.

Effect of Simvastatin and Doxycycline on HDL after Aβ induction in mice

The sham group did not show any significant increase in the HDL when compared to normal (28.80 ± 3.48 vs. 27.81 ± 2.66). The disease group has shown an increase in the amount of HDL when compared to the disease (39.59 ± 0.96 vs. 41.40 ± 1.06). Simvastatin-treated group has shown a decrease in the amount of HDL when compared to the disease (47.25 ± 1.62 vs. 64.10 ± 2.33). Doxycycline-treated group has shown an increase in the amount of HDL when compared to the disease (52.39 ± 0.85 vs. 50.91 ± 1.99). A low-dose combination of Simvastatin and Doxycycline has shown a decrease in the amount of HDL when compared to the disease (51.91 ± 1.99 vs. 64.10 ± 2.33). The effect of Simvastatin and Doxycycline on triglyceride levels are reported in Figure 4 and Table 4.

Effect of Simvastatin and Doxycycline on triglycerides after Aβ induction in mice

The sham group did not show any significant increase in triglycerides when compared to normal (48.73 ± 2.30 vs. 50.91 ± 1.99). The disease group has shown an increase in the number of triglycerides when compared to normal (64.10 ± 2.33 vs. 50.91 ± 1.99). Simvastatin-treated group has shown a decrease in the amount of total cholesterol when compared to the disease (47.25 ± 1.62 vs. 64.10 ± 2.33). Doxycycline-treated group has shown a decrease in the amount of total cholesterol when compared to the disease (52.39 ± 0.85 vs. 50.91 ± 1.99). A low-dose combination of Simvastatin and Doxycycline has shown a decrease in the amount of triglycerides when compared to the disease (51.91 ± 1.99 vs. 64.10 ± 2.33). The effect of Simvastatin and Doxycycline on triglyceride levels are reported in Figure 4 and Table 4.

Figure 2. Effect of Simvastatin and Doxycycline on time spent in target zone after Aβ induction in mice. All values are expressed in the form of Mean ± SEM, n = 7; data were analyzed by employing two-way ANOVA, and “a” represents p-value < 0.05 when compared to normal versus disease and “b” represents p-value < 0.05 when compared to disease versus treatment groups.

Table 3. Effect of Simvastatin and Doxycycline on time spent in target zone after Aβ induction in mice.

<table>
<thead>
<tr>
<th>Days</th>
<th>Normal</th>
<th>Sham</th>
<th>Disease</th>
<th>Standard</th>
<th>Simvastatin</th>
<th>Doxycycline</th>
<th>Low dose (Simva and Doxy)</th>
<th>High dose (Simva and Doxy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>19.21 ± 0.85</td>
<td>15.21 ± 2.05</td>
<td>17.32 ± 0.51</td>
<td>15.34 ± 1.44</td>
<td>14.68 ± 0.95</td>
<td>14.52 ± 0.27</td>
<td>16.2 ± 0.71</td>
<td>16.01 ± 0.97</td>
</tr>
<tr>
<td>7</td>
<td>16.32 ± 0.37</td>
<td>14.2 ± 0.88</td>
<td>14.95 ± 1.49</td>
<td>14.55 ± 0.84</td>
<td>12.18 ± 0.91</td>
<td>13.22 ± 0.68</td>
<td>14.64 ± 0.61</td>
<td>14.74 ± 1.4</td>
</tr>
<tr>
<td>28</td>
<td>19.04 ± 0.60</td>
<td>15.65 ± 1.00</td>
<td>10.61 ± 1.62*</td>
<td>13.77 ± 0.97</td>
<td>14.66 ± 0.73</td>
<td>13.61 ± 0.92</td>
<td>15.24 ± 0.80</td>
<td>17.15 ± 0.79</td>
</tr>
</tbody>
</table>

All values are expressed in the form of Mean ± SEM, n = 7; data were analyzed by employing two-way ANOVA, and “a” represents p-value < 0.05 when compared to normal versus disease and “b” represents p-value < 0.05 when compared to disease versus treatment groups.
of Simvastatin and Doxycycline on HDL levels are reported in Figure 5 and Table 4.

**Histopathology**

The histopathological data is shown in Figure 6. The data revealed that the disease group showed degeneration of pyramidal neurons and the presence of macrophages, whereas the Simvastatin, Doxycycline group, and combination (high dose) group showed significant recovery from the damage caused by $\alpha_1\beta_{1-42}$ induction.

![Figure 3](image3.png) **Figure 3.** Effect of Simvastatin and Doxycycline on total cholesterol after Aβ induction in mice. All values are expressed in the form of Mean ± SEM, $n = 7$; statistical analysis was executed employing one-way ANOVA, and “a” represents $p$-value <0.05 when compared to disease versus treatment groups and “b” represents $p$-value <0.05 when compared to standard versus treatment.

![Figure 4](image4.png) **Figure 4.** Effect of Simvastatin and Doxycycline on triglycerides after Aβ induction in mice. All values are expressed in the form of Mean ± SEM, $n = 7$; statistical analysis was executed employing one-way ANOVA, and “a” represents $p$-value <0.05 when compared to disease versus treatment.

![Figure 5](image5.png) **Figure 5.** Effect of Simvastatin and Doxycycline on HDL after Aβ induction in mice. All values are expressed in the form of Mean ± SEM, $n = 7$; statistical analysis was executed by employing one-way ANOVA, and “b” represents $p$-value <0.05 when compared to standard versus treatment.

![Figure 6](image6.png) **Figure 6.** Photomicrographs showing the histological architecture of the brain hippocampus region. 1 – nerve cell; 2 – glial cell; 3 – blood Vessel; 4 – infiltration with the presence of macrophages; and 5 – degeneration of pyramidal neurons.

**Table 4.** Effect of Simvastatin and Doxycycline on various biochemical parameters.

<table>
<thead>
<tr>
<th>Biochemical estimation</th>
<th>Normal</th>
<th>Sham</th>
<th>Disease</th>
<th>Standard</th>
<th>Simvastatin</th>
<th>Doxycycline</th>
<th>Low dose (Simva and Doxy)</th>
<th>High dose (Simva and Doxy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>40.31 ± 2.73</td>
<td>38.92 ± 2.37</td>
<td>59.89 ± 0.95</td>
<td>48.27 ± 1.11</td>
<td>37.69 ± 0.95</td>
<td>52.39 ± 0.85</td>
<td>49.09 ± 0.94</td>
<td>41.07 ± 1.91</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>50.91 ± 1.99</td>
<td>48.73 ± 2.30</td>
<td>64.10 ± 2.33</td>
<td>55.31 ± 2.24</td>
<td>47.25 ± 1.65</td>
<td>57.84 ± 2.63</td>
<td>51.91 ± 1.99</td>
<td>49.33 ± 2.80</td>
</tr>
<tr>
<td>HDL</td>
<td>27.81 ± 2.66</td>
<td>28.80 ± 3.48</td>
<td>41.40 ± 1.06</td>
<td>44.46 ± 1.02</td>
<td>39.59 ± 0.96</td>
<td>43.93 ± 1.93</td>
<td>41.44 ± 1.00</td>
<td>33.52 ± 1.98</td>
</tr>
</tbody>
</table>

All values are expressed in the form of Mean ± SEM, $n = 7$, statistical analysis was executed employing one-way ANOVA, and ‘a’ represents $p$-value <0.05 when compared to disease versus treatment groups and ‘b’ represents $p$-value <0.05 when compared to standard versus treatment groups.

![Table 4](image7.png)
DISCUSSION

AD is a complicated illness caused by a combination of hereditary and environmental factors. Despite recent promising developments in the study of AD, the link between cholesterol and APP processing remains poorly understood. During AD conditions, the cholesterol levels in the brain increase, and these regions are called lipid rafts. These lipid rafts are hosts for β and γ secretases. As a result, mono fibrils develop, which leads to Aβ oligomerization and, eventually, Aβ accumulation. Cholesterol inhibits α-secretase and non-Amyloid pathways as well. Simvastatin reduces cholesterol levels; thereby, the amount of Aβ peptides decreases. A decrease in the amount of Aβ peptides decreases the progression of AD. Doxycycline is endowed with anti-amyloidogenic properties and better crosses the blood–brain barrier. The present study showed that administration of Aβ by single unilaterally after i.c.v surgery to the female C57BL/6 mice caused AD symptoms such as olfactory damage and cognitive impairment. The olfactory damage was assessed by the time taken to unbury the pellet. The cognitive impairment was assessed by the time spent in the target quadrant and the latency to reach the target quadrant. Olfactory function was assessed by performing the buried pellet test. In this study, after the administration of Aβ, it was observed that there was a decrease in the olfactory function in the disease when compared to the sham control and normal group. The standard group has shown a significant increase in olfaction ability when compared to the disease. The treatment groups have shown a significant increase in olfactory function when compared to the disease after the completion of treatment.

The cognitive impairment was assessed by the MWM. The time spent in the quadrant zone was decreased in disease when compared to the sham control and control group. The standard drug has shown a significant increase in time spent in the target quadrant. The treatment groups such as Simvastatin and Doxycycline and low dose combination (Simva and doxy) have shown less significance when compared to the standard. A high combination dose of (Simva and doxy) has shown an increase in time spent in the target quadrant. Similarly, the latency to reach the target quadrant was also assessed by the MWM. The latency to reach the target quadrant in the disease was increased when compared to the normal and sham controls. The standard group has shown a significant decrease in latency to reach the target quadrant. The treatment groups such as Simvastatin and Doxycycline and low dose combination (Simva and doxy) have shown less significance when compared to the standard. A high combination dose of (Simva and doxy) has shown decreased latency to reach the target quadrant.

Total cholesterol, triglycerides, and HDL were estimated in serum and were measured by enzymatic assay from serum by using commercial RANDOX KITS. The amount of total cholesterol, triglycerides, and HDL was increased in the disease when compared to the normal. The standard drug does not have any significant effect on total cholesterol, triglycerides, and HDL. The treatment group Simvastatin and low dose combination (simva and doxy) has a significant decrease in the amount of total cholesterol and triglycerides and HDL. These results show that a high-dose combination of (simva and doxy) exhibits cholesterol-lowering properties by blocking the HMG CoA reductase pathway, thereby regulating cholesterol. Hence, a high dose combination of (simva and doxy) has an anti-Alzheimer’s effect by regulating the cholesterol and clearance of Aβ aggregation by blocking the HMG CoA reductase pathway. AD is a complicated illness caused by a combination of hereditary and environmental factors. Despite recent promising developments in the study of AD, the link between cholesterol and APP processing remains poorly understood. During AD conditions, the cholesterol levels in the brain increase, and these regions are called lipid rafts. These lipid rafts are hosts for β and γ secretases. As a result, mono fibrils develop, which leads to Aβ oligomerization and, eventually, Aβ accumulation. Cholesterol inhibits α-secretase and non-Amyloid pathways as well.

CONCLUSION

These results show that Aβ administration through i.c.v induces Alzheimer’s, and upregulation of cholesterol is seen in disease-induced animals. Administration of Simvastatin and Doxycycline in various doses attenuates the olfactory function and cognitive impairment. High-dose administration of (Simvastatin and Doxycycline) reduces the total cholesterol, triglycerides, and HDL levels. Hence, the study shows that the administration of a high dose administration of (Simvastatin and Doxycycline) produces an anti-Alzheimer’s effect in Aβ-induced Alzheimer’s model.

AUTHOR CONTRIBUTIONS

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All the authors are eligible to be an author as per the International Committee of Medical Journal Editors (ICMJE) requirements/guidelines.

FINANCIAL SUPPORT

There is no funding to report.

CONFLICTS OF INTEREST

The authors report no financial or any other conflicts of interest in this work.

ETHICAL APPROVALS

The study protocol was approved by the IAEC of JSSCPM (Approval no: JSSAHER/CPT/AEC/081/2021).

DATA AVAILABILITY

All data generated and analyzed are included in this research article.

PUBLISHER’S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.
REFERENCES


How to cite this article: